{"Clinical Trial ID": "NCT00290758", "Intervention": ["INTERVENTION 1:", "Army A (Genistein)", "Patients receive genistein orally once daily for up to 6 months.", "INTERVENTION 2:", "Army B (Placebo)", "Patients receive placebo orally once daily for up to 6 months."], "Eligibility": ["Incorporation criteria:", "No known intolerance to soybeans", "At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by one of the following:", "\u25cf Estimation of the risk of developing breast cancer over 5 years according to the Gail model, as defined by 1 of the following criteria:", "\u2022 Tail score >= 1.66%", "= 0.1% for women aged 20-29", "= 1.0% among women aged 30 to 39 years", "\u2022 Estimation of the risk of developing breast cancer over 5 years according to the Claus model:", "Claus score >= 1.66%", "= 0.1% for women aged 20-29", "= 1.0% among women aged 30 to 39 years", "A prior diagnosis of unilateral in situ or invasive breast cancer OR a history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity", "History of lobular carcinoma in situ", "No evidence of breast cancer, as determined by a negative mammogram in the last 6 months and a history and physical", "No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago", "Pre- or post-menopausal", "ECOG Performance Status 0-1", "Hemoglobin > 10.0 g/dL", "Number of platelets > 100 000/mm^3", "Absolute number of neutrophils > 1000/mm^3", "Creatinine < 2.0 mg/dL", "- SGPT < 82 U/L", "- SGOT < 68 U/L", "Bilirubin < 3 mg/dL* [Note: * Patients with a higher rate of bilirubin due to family metabolism may be eligible at the discretion of the investigator]", "Life expectancy > 2 years", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception against barriers.", "Must be ready to keep a food diary", "No venous thrombosis in the past year", "No unrecognized or poorly controlled thyroid disease", "No other cancers in the last 5 years except non-melanomatous skin cancer or non-invasive cervical cancer", "No other medical condition which, in the opinion of the investigator, would compromise either the patient or the integrity of the data obtained", "None of the following for >= 2 weeks prior to the first random fine needle aspiration and during study participation:", "Oral contraceptives", "Soybean supplements", "\u2022 Foods with a high soy content", "Fish oil supplements", "Multivitamins", "Vitamins C and E", "Aspirin daily or non-steroidal", "Anti-inflammatory drugs", "No other competing search agent", "No warfarin or other concomitant blood diluents", "Women", "- Exclusion criteria:", "Women who have already been diagnosed with breast cancer will not be eligible unless all systemic treatment (including endocrine treatment) is completed at least one year earlier.", "Currently pregnant, or planning to become pregnant during the study period", "History of venous thrombosis in the past year", "Medical conditions which, in the opinion of the investigators, would compromise either the patient or the integrity of the data obtained", "\u2022 History of other cancers in the last five years, excluding non-melanomatous skin cancer and non-invasive cervical cancer", "A known intolerance to soy", "If thyroid disease is not recognized or uncontrolled, subjects may be on synthroid, but thyroid function should be on a normal scale or the patient's physician should document that the patient's thyroid is controlled.", "Currently receives any other research officer", "Currently on coumadine, or other blood diluents", "The history of breast augmentation implants.", "- Patients with < 4,000 epithelial cells in the first or second random aspiration of the fine breeder (rRNA) will not be included in the study."], "Results": ["Performance measures:", "Change in breast epithelial cell proliferation as measured by Ki-67", "\u25cf Samples of breast epithelial tissue are used to measure the expression of the Ki-67 cell proliferation marker, counting the percentage of positive MIB-1 immunostinated cells, indicating the Ki-67 labeling index. The average change in Ki-67 labeling index is evaluated from inclusion to a 6-month follow-up.", "Time limit: 6 months - baseline", "Results 1:", "Title of the arm/group: Arm A (Genistin)", "Description of the arm/group: Patients receive genistein orally once daily for up to 6 months.", "Total number of participants analysed: 49", "Average (standard deviation)", "Unit of measure: Ki-67 post-operative menopausal- Cancer labelling index: 4 participants", "- 325 (.343)", "Postmenopausal menopausal with ER+ Cancer: 2 participants", "-418 (.191)", "After menopause without cancer: 14 participants", "-.092 (.525)", "Premonopausal with ER- Cancer: 2 participants", "-335 (.930)", "\u2022 Premenopausal ER+ cancer: 4 participants", "-387 (.806)", "\u2022 Premenopausal without cancer: 23 participants", "- 1,171 (2.922)", "Results 2:", "Title of arm/group: Arm B (Placebo)", "Description of arm/group: Patients receive oral placebo once daily for up to 6 months.", "Total number of participants analysed: 49", "Average (standard deviation)", "Unit of measure: Ki-67 post-operative menopausal- Cancer labelling index: 2 participants", "\u00b7 289 (.541)", "Postmenopausal menopausal with ER+ Cancer: 5 participants", "-461 (458)", "Postmenopausal cancer-free: 15 participants", "- 122 (.735)", "Premonopausal with ER- Cancer: 2 participants", "873 (.786)", "\u2022 Premenopausal ER+ cancer: 4 participants", "-204 (1.329)", "\u2022 Premenopausal without cancer: 21 participants", "- 0.557 (1.546)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/62 (9.68 per cent)", "Musculoskeletal disorders * 1/62 (1.61%)", "Mood change: depression * 1/62 (1.61%)", "Renal - Other * 1/62 (1.61%)", "\u25a1 Obstruction, GU: Uterus * 1/62 (1.61%)", "Gender * 0/62 (0.00 per cent)", "Pulmonary/Respiratory Upper: Dyspnoea * 1/62 (1.61%)", "Ulceration * 1/62 (1.61%)", "Adverse Events 2:", "Total: 1/64 (1.56%)", "* 0/64 (0.00 %)", "Mood change: depression * 0/64 (0.00 %)", "Renal - Other * 0/64 (0.00 %)", "\u25ba Obstruction, GU: Uterus * 0/64 (0.00%)", "Gender * 1/64 (1.56%)", "Pulmonary/Respiratory Upper: Dyspnoea * 0/64 (0.00 %)", "Ulceration * 0/64 (0.00 %)"]}